2.50
Hdl Handle:
http://hdl.handle.net/10541/86138
Title:
Natural HPV immunity and vaccination strategies.
Authors:
Stern, Peter L; Brown, Michael D; Stacey, Simon N; Kitchener, Henry C; Hampson, Ian N; Abdel-Hady, El-Said; Moore, James V
Abstract:
BACKGROUND: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. OBJECTIVES: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. CONCLUSION: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.
Affiliation:
Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, M20 4BX, Manchester, UK.
Citation:
Natural HPV immunity and vaccination strategies. 2000, 19 (1-2):57-66 J. Clin. Virol.
Journal:
Journal of Clinical Virology
Issue Date:
Oct-2000
URI:
http://hdl.handle.net/10541/86138
PubMed ID:
11091148
Type:
Article
Language:
en
ISSN:
1386-6532
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorStern, Peter Len
dc.contributor.authorBrown, Michael Den
dc.contributor.authorStacey, Simon Nen
dc.contributor.authorKitchener, Henry Cen
dc.contributor.authorHampson, Ian Nen
dc.contributor.authorAbdel-Hady, El-Saiden
dc.contributor.authorMoore, James Ven
dc.date.accessioned2009-11-13T12:57:27Z-
dc.date.available2009-11-13T12:57:27Z-
dc.date.issued2000-10-
dc.identifier.citationNatural HPV immunity and vaccination strategies. 2000, 19 (1-2):57-66 J. Clin. Virol.en
dc.identifier.issn1386-6532-
dc.identifier.pmid11091148-
dc.identifier.urihttp://hdl.handle.net/10541/86138-
dc.description.abstractBACKGROUND: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. OBJECTIVES: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. CONCLUSION: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.en
dc.language.isoenen
dc.subjectVulvar Canceren
dc.subjectTumour Virus Infectionsen
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunity, Innate-
dc.subject.meshOncogene Proteins, Viral-
dc.subject.meshPapillomaviridae-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshTumor Virus Infections-
dc.subject.meshVaccination-
dc.subject.meshViral Vaccines-
dc.subject.meshVulvar Neoplasms-
dc.titleNatural HPV immunity and vaccination strategies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, M20 4BX, Manchester, UK.en
dc.identifier.journalJournal of Clinical Virologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.